Neuropsychiatry of Huntington's disease by Rosenblatt, Adam
n attempting a treatment of the neuropsychia-
try of Huntington’s disease (HD),it is necessary to avoid
the pitfalls which stem from our imperfect understand-
ing of the condition.The first is a tendency toward exces-
sive reductionism. Since we are unable to grasp its
essence,Huntington’s disease comes to be regarded as a
catalogue of its motor, cognitive, and behavioral signs
and symptoms. The striking chorea and dystonia are
given primacy, and HD is thought of merely as a move-
ment disorder,with the cognitive impairments and per-
sonality changes relegated to the status of accessory fea-
tures. In fact, they are universal. Both may precede the
emergence of involuntary movements,
1,2 and any com-
plete theory of Huntington’s disease must explain all
three. Likewise, rating scales and other instruments are
useful in the assessment of psychiatric problems in HD,
but not if they prevent us from moving from symptoms
to syndromes. To speak only of “dysphoria” or “irri-
tability” in HD, is to confuse the illness with the rating
scale used to assess it,and puts one in mind of the com-
ment attributed to Binet that “intelligence is what my
test measures.”
If over-reliance on rating scales and catalogues of symp-
toms constitutes an excessively Aristotelian approach,we
must also avoid its Platonic opposite,which is to shoe-
horn every psychiatric manifestation of HD into an exist-
ing idiopathic category,such as mania,or obsessive-com-
pulsive disorder (OCD), as if each of these categories
existed a priori,waiting to be unlocked by the HD muta-
tion.We have almost no idea what causes these disorders
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Psychiatric manifestations are an integral part of
Huntington’s disease. They may be divided into those syn-
dromes which resemble idiopathic disorders, but for which
HD patients may be particularly at risk, those constella-
tions which are peculiar to HD and related conditions,
such as the executive dysfunction syndrome, and those
symptoms that can truly be regarded as nonspecific, such
as delirium. Most of these problems are believed to arise
from subcortical neuropathologic changes. Major depres-
sion is a common psychiatric diagnosis, but the executive
dysfunction syndrome, a difficult-to-define condition char-
acterized by often simultaneous apathy and disinhibition,
may be even more widespread. There are no large con-
trolled studies of psychiatric treatments in HD, but case
series, anecdotal reports, and clinical experience indicate
that many of these syndromes respond readily to treat-
ment. Further study of the neuropsychiatry of HD may
help to reveal the underpinnings of psychiatric conditions
found in the general population.
© 2007, LLS SAS Dialogues Clin Neurosci. 2007;9:191-197.in the otherwise healthy population,and thus possess no
definitive means of diagnosis.Therefore,before we can
say that we have identified “the same”conditions in HD,
we must ask a series of questions.Does the HD-related
condition have all the essential features of the idiopathic
condition? Does it show a similar course over time? Is
there evidence from imaging or laboratory studies that
the conditions are related? Do they respond to the same
treatments? Only by striking the right balance between
these nominalist and realist extremes may we hope to
understand and to devise effective treatment for the psy-
chiatric manifestation of HD.
To reinforce this point,we will avoid the usual method of
dividing the topic up by mental symptoms or by psychi-
atric diagnoses,and instead will organize our treatment
into three heuristic categories:those psychiatric condi-
tions found in persons with HD which strongly resemble
idiopathic disorders found in the general population,
such as Major Depression;those conditions found in HD
which have no closely analogous conditions among the
idiopathic disorder,and which appear to be either unique
to HD or to the family of frontal-subcortical diseases,and
injuries of the brain,such as the executive dysfunction
syndrome,and those conditions,common in all patients
with impaired brain function, which can properly be
described as nonspecific,such as delirium.
3
Overview of Huntington’s disease
HD is a hereditary neurodegenerative disorder caused
by the abnormal expansion of a trinucleotide (CAG)
repeat in the huntingtin gene of chromosome 4.The most
common time of onset is in the fourth or fifth decade of
life, but the first symptoms can appear anywhere from
childhood to old age,with the age of onset inversely cor-
related with the size of the triplet repeat expansion.The
progression of Huntington’s disease is inexorable, and
usually leads to death within 15 to 20 years,with patients
who are immobile and severely demented.
The movement disorder of HD includes both involun-
tary movements, such as chorea and dystonia, and
impairments of voluntary movement, characterized by
clumsiness, dysarthria, swallowing difficulties, falls,
bradykinesia, and rigidity. Chorea generally predomi-
nates early, and is eclipsed by motor impairment as the
disease becomes more advanced.
The dementia caused by HD is often described as a sub-
cortical dementia, in contrast to a cortical process such
as Alzheimer’s disease (AD).This is a somewhat con-
troversial distinction,
4 but patients have relatively pre-
served memory yet experience more difficulty in execu-
tive function, impairment on tasks requiring attention
and concentration,and erosion of personality.
5,6
Conditions found in persons with HD 
which strongly resemble 
idiopathic psychiatric disorders
Depression
A major depressive syndrome has been part of the nosol-
ogy of HD from Dr Huntington’s first description of the
disease.
7 In fact,the lifetime prevalence is high,perhaps
about 30% to 40%,
8,9 with a suicide rate 4 to 6 times that
of the general population.
10 Severe cases may be accom-
panied by mood-congruent delusions or auditory halluci-
nations.Looked at subsyndromically,depressed mood is
reported in approximately 35% to 60% of persons with
HD,depending on the instrument used.
11,12
Other features of HD may lead to underdiagnosis or over-
diagnosis of major depression. For example, common
symptoms such as weight loss or apathy may be taken as
evidence of a depressive syndrome,or,on the other hand,
a classical major depression may be dismissed as the
“understandable”reaction of the patient to having HD.
Depression in HD is associated with reduced glucose
metabolism in the orbitofrontal and inferior prefrontal
regions.
13This finding is consistent with hypometabolism
found in the prefrontal cortex of depressed patients with-
out a primary neurologic disorder.
14
It has been said that major depression can precede the
movement disorder in HD, sometimes by years.While
subtle psychiatric symptoms are more common in
presymptomatic individuals,
2 there is little evidence to
support this larger contention, and major depression is
a common condition in the general population.The pres-
ence of depressive symptoms in an individual at risk for
HD should not be used to make a diagnosis or serve as
an indication for genetic testing.
The literature on the treatment of depression in HD by
pharmacologic or psychosocial means is scant,but patients
may respond to almost any standard class of medication
15
and to electroconvulsive therapy,
16 with the caveat that
they will likely be more sensitive to adverse central ner-
vous system (CNS) effects of treatment,such as delirium
or agitation,than otherwise healthy individuals.
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Mania and bipolar syndromes have a lifetime prevalence
of 5% to 10% in HD,
8,17 higher than would be predicted by
chance.Patients may present with an elevated or irritable
mood, impulsiveness, increased activity, hypersexuality,
decreased need for sleep,and a grandiose self-attitude,and
in severe cases may have delusions and hallucinations.As
with major depression,mania can be the first indication of
HD.Precision is required,however,in rendering a diag-
nosis of mania in HD,because personality changes such as
disinhibition,irritability,and facetiousness which resemble
mania are common in the disease.A classic presentation
of mania would include three essential elements:an ele-
vated or irritable mood,a grandiose (or paranoid) thought
content, and symptoms of overactivity, such as racing
thoughts,pressured speech,decreased need for sleep,or
hypersexuality.This triad is frequently lacking in patients
presenting primarily with “frontal”disinhibition.
The mainstay of treatment is a mood-stabilizing agent,
usually an anticonvulsant such as divalproex sodium or
a neuroleptic.Concern has been expressed about the use
of lithium carbonate because of poor response and pos-
sible toxicity. Patients with HD are certainly more sus-
ceptible to dehydration and delirium,but responses may
have been limited in the past because of imprecise diag-
nosis.The agent should at least be considered in cases
with a classic presentation of mania.
Primary psychotic disorders
Delusions have been reported cross-sectionally in 11%
of patients with HD and hallucinations in about 2%,
using the neuropsychiatric inventory (NPI),
11,18 or about
3% for each using an HD-specific instrument.
12 A 9%
lifetime prevalence of schizophrenia has been reported
in HD,
9 but it is difficult to interpret such a statement,
since we do not understand the causes of idiopathic
schizophrenia,and even its core features are disputable.
The most common psychotic presentation in HD
appears to be poorly systematized paranoia and over-
valued ideas that are commonly accompanied by aggres-
sion, irritability, and poor impulse control,
15 and might
better be thought of as part of the executive dysfunction
syndrome of HD. Likewise, apathy and flattened affect
can be found in schizophrenia, or in HD patients with-
out psychotic symptoms. Isolated, well-defined delu-
sional states and schizophrenia-like psychotic states are
uncommon, but, in our experience, have included ero-
tomanic delusions, delusional parasitosis, delusions of
bodily decay,and third-party auditory hallucinations.
Psychotic symptoms in HD patients are usually treated
with neuroleptics,but most practitioners have a preference
for the atypical agents because of the lower risk of
extrapyramidal side effects. Many patients respond to
antipsychotic treatments,but some delusional states seem
particularly incorrigible,consistent with the inflexibility
manifested by many people with HD.
OCD
The rate of OCD is another controversial proposition in
HD.Repetitive behaviors and speech,inflexibility,per-
severation,and preoccupation with idiosyncratic topics
are certainly common in Huntington’s disease,
12 but these
may be just another aspect of the spectrum of “frontal”
symptoms that make up the executive dysfunction dis-
order.It has been reported that 22.3% of HD patients in
a large study had obsessive or compulsive symptoms at
their first visit,
19 but the instrument used,the behavioral
section of the Unified Huntington’s Disease Rating Scale
(UHDRS),
20 is poorly validated and lacks the rigor to dis-
tinguish true obsessions and compulsions from the per-
sonality changes commonly seen in HD. In a smaller
study
21 50% of HD patients endorsed at least one obses-
sive or compulsive symptom on the Yale-Brown scale
22
and symptoms correlated with deficiencies in executive
functioning on cognitive testing.However,this scale was
not designed to differentiate OCD from similar phe-
nomena, and only the checklist questions and not the
severity measures were administered.
Clearly,classical cases of OCD exist in Huntington’s dis-
ease
23 and the frontal lobe, caudate, and globus pallidus
have been implicated in OCD.
24 Estimates of the rate of
OCD in HD and the degree to which certain dysexecutive
symptoms should be given their own obsessive-compulsive
category depend to a large extent on how much credence
is given to the idea of an “obsessive-compulsive spectrum.”
Serotonergic agents such as selective serotonin reuptake
inhibitors (SSRIs) and clomipromine are the mainstay of
pharmacotherapy, but often behavioral management
techniques,such as distraction and setting a routine,and
managing the expectations of friends and family mem-
bers through education,may be a more effective strategy.
Cognitive deficits at this stage make cognitve therapies
difficult.
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other frontal-subcortical disorders
The executive dysfunction syndrome
Of all the psychiatric manifestations of HD, the execu-
tive dysfunction syndrome of HD, while difficult to
define and characterize, may be the most common.
Individuals with this syndrome may become apathetic,
irritable,disinhibited,impulsive,obsessional,and perse-
verative. In a 134-person study, symptoms which might
be termed “apathetic,”such as loss of energy and initia-
tive, poor perseverance and quality of work, impaired
judgment, poor self-care, and emotional blunting were
the most common.
12 Factor analysis revealed an “apa-
thy”factor,an “irritable”factor and a “depression”fac-
tor,and only the “apathy”factor correlated with disease
duration. In another study,
25 the apathy factor, but not
the other two,correlated with both motor and cognitive
impairment.The implication is that those symptoms may
be a more or less inherent part of HD.
Earlier treatments of the neuropsychiatry of HD tended
to recognize that these seemingly disparate symptoms
travel together, but simply lumped them all into a sec-
tion called “aggression, irritability, and apathy,”
26 or
referred to them as the “frontal lobe syndrome,”
27 in
analogy to disorders with similar manifestations affect-
ing primarily that part of the brain. In designing an
inventory for the assessment and differentiation of
frontal lobe dementia,Kertesc and colleagues designed
the Frontal-Behavioral Inventory,
28 a 24-item question-
naire which divides symptoms into positive or disinhib-
ited behaviors,such as perseveration,irritability,and joc-
ularity,and negative or deficit behaviors,such as apathy,
aspontaneity,and indifference.This schema captures the
seemingly paradoxical coexistence of apathy and disin-
hibition in the patient with HD.However,instead of the
pseudoanatomical term “frontal,” we now prefer the
more functional term “executive dysfunction syn-
drome.”
3 Although they may be different sides of the
same coin, we will deal with some of the major symp-
toms of the executive dysfunction syndrome separately,
for the purpose of discussing treatment.
Apathy
Apathy is more distressing to friends and family than to
the patient experiencing it. Sometimes the only neces-
sary intervention is to educate caregivers and help them
to revise their expectations,by explaining that apathy is
a predictable symptom of HD,and that it is not synony-
mous with depression. Anecdotal reports have been
published of the successful treatment of apathy with
amantadine, amphetamines, bromocriptine, bupropion,
methylphenidate, and selegiline.
29 A nonsedating SSRI,
such as fluoxetine,sertraline,or citaprolam may also be
considered.
Other authors have suggested reducing medications that
might blunt emotion or slow cognitive processing, such
as the neuroleptics.
30 Nonpharmacologic approaches
include avoiding open-ended questions or tasks,provid-
ing cueing,maintaining a regular schedule,and increased
environmental stimulation,such as involvement in a day
program.
Irritability
The key to management of irritability and aggression is
to place the behavior in context, so as to identify and
avoid precipitants.There are no large,systematic studies
of the efficacy of psychotropic medications in HD-
related aggression and irritability.Nevertheless,antipsy-
chotics,“mood stabilizers,” and antidepressants, partic-
ularly the SSRIs,are frequently prescribed.
Perseveration
Some perseverative or fixated patients can be dis-
tracted, or will extinguish if given enough time. Others
are incorrigible. In these cases, the family should be
encouraged to “pick their battles.” Confrontations
should be saved for situations having to do with safety.
This will be an easier point to get across if the family
understands that these behaviors are due to the HD
itself and that their loved one cannot “be reasonable.”
Sometimes perseverative patients are treated with
SSRIs for their presumptive “antiobsessive” effect.
There is some theoretical basis for a dopamine-aug-
menting strategy in the treatment of executive dys-
function.A case has been reported of successful treat-
ment with amantadine of an HD patient with an
extreme syndrome characterized by perseveration,dis-
inhibition, and severe aggression,
3 as well as a case
series showing positive results in psychiatric inpatients
with executive dysfunction in the context of various
forms of dementia.
31
Clinical research
194Nonspecific psychiatric conditions 
also found in HD
Delirium
Delirium is common in HD,and may result from volume
depletion,poor nutrition,medical complications,metabolic
disturbances such as urinary tract infections and pneumo-
nias,and medication effects.Occult subdural hematomata
from unwitnessed falls and head injuries are also a com-
mon and dangerous cause of delirium.The rule of thumb
is that nothing changes rapidly in HD.A sudden change in
behavior or decline in cognitive abilities should prompt an
evaluation for delirium.The definitive treatment for delir-
ium is to discover and correct the cause,but low-dose neu-
roleptics are probably the safest pharmacologic treatment
for short-term management of an agitated delirium.
Demoralization
Despite the caveat against assuming a reactive explana-
tion for all depressive symptoms in HD,patients with HD
can and do become demoralized.This occurs particularly
at times of loss,such as when a person with HD is forced
to stop working,or give up driving.Patients who are also
suffering from a dysexecutive syndrome may find it espe-
cially difficult to move on,and hospitalizations and suicide
attempts have resulted from such losses. Other times,
patients who are doing well may bring up suicide as an
option for the future,“before things get too bad.”The clin-
ician should listen sympathetically to such statements,
which reflect the patient’s fear of impending helplessness,
but should not overreact. Few HD patients actually kill
themselves in such a premeditated way,perhaps because
they tend to become increasingly unaware of their deficits
as cognitive and executive function declines.
32
Sexual problems
The most common sexual disorders in HD,hypoactive sex-
ual desire and inhibited orgasm, have been reported in
63% and 56% of men,and 75% and 42% of women.
33At
the other end of the spectrum,sexual aberrations,such as
sexual assault,promiscuity,incest,indecent exposure,and
voyeurism,have been described in HD,no doubt fueled
by the disinhibition,perseveration,and impaired judgment
which characterize the disorder.There have been no sys-
tematic studies of management of inappropriate sexual
behaviors in HD.In severe cases,treatment with an antian-
drogen agent,such as leuprolide acetate,may be appro-
priate.
Sleep problems
Patients with HD may have insomnia for a wide variety of
reasons,including depression,lack of daytime stimulation,
deterioration of the sleep-wake cycle, and involuntary
movements.Although these movements in HD tend to
fade during sleep,they may present an obstacle to falling
asleep or to going back to sleep after a nighttime awak-
ening.A formal sleep study can be useful for confirmation.
In such cases,bedtime use of neuroleptics or other drugs
to suppress chorea may solve the problem.Agents such as
sedating antidepressants and low-potency neuroleptics
may be used judiciously.Oftentimes,however,the act of
keeping the person awake and active during the day,such
as by enrolling them in a day program,is the most power-
ful intervention for sleep.Benzodiazepine and other seda-
tive-hypnotics are almost always the wrong answer in HD.
Apathetic patients with HD often sleep excessively or
spend an inordinate amount of time in bed.This may be
acceptable to the patient and family if it is understood as
a feature of the disease.In cases where harm could result
because the person is not coming to meals or practising
good hygiene, judicious use of amphetamines may be
appropriate.
34
Conclusion
We have attempted not to simply catalogue the psychiatric
manifestations of HD, but to reorganize them, in a way
that reflects evolving thought on the subject and a state-
of-the-art understanding of the disease.Psychiatric issues
in HD are so common that the clinician should expect to
see them at every turn.Not only are they the aspect of HD
most susceptible to treatment,but they are also one of the
most exciting avenues for research.Each psychiatric syn-
drome in HD,such as major depression,or executive dys-
function,can be regarded as an “experiment of nature,”
the explication of which has a great deal to teach us,not
only about Huntington’s disease,but about psychiatry as
a whole. ❏
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Neuropsiquiatría de la Enfermedad de
Huntington
Las manifestaciones psiquiátricas constituyen una
parte integral de la Enfermedad de Huntington (EH).
Ellas pueden dividirse en aquellos síndromes que se
asemejan a los trastornos idiopáticos, para los cuales
los pacientes con EH pueden estar particularmente en
riesgo, aquellas constelaciones que son características
de la EH y condiciones relacionadas, tal como el sín-
drome de disfunción ejecutiva, y aquellos síntomas
que pueden ser considerados verdaderamente como
inespecíficos, como el delirium. Se cree que la mayo-
ría de estos problemas surgen a partir de cambios neu-
ropatológicos subcorticales. La depresión mayor es un
diagnóstico psiquiátrico frecuente; sin embargo, el sín-
drome de disfunción ejecutiva, una condición difícil
de definir que se caracteriza por la aparición a
menudo simultánea de apatía y desinhibición, puede
ser aun mucho más frecuente. No hay gran cantidad
de estudios controlados de los tratamientos psiquiá-
tricos en la EH, pero series de casos, reportes anecdó-
ticos y la experiencia clínica indican que muchos de
estos síndromes responden fácilmente al tratamiento.
Nuevos estudios acerca de la neuropsiquiatría de la EH
pueden ayudar a esclarecer las bases de las condicio-
nes psiquiátricas encontradas en la población general.
Neuropsychiatrie de la maladie de
Huntington
Les manifestations psychiatriques font partie inté-
grante de la maladie de Huntington (MH). Elles peu-
vent être divisées en syndromes ressemblant à des
troubles idiopathiques, mais touchant particulière-
ment les patients atteints de MH, en cortèges de
symptômes spécifiques à la MH et aux troubles qui
s’y rapportent, comme le syndrome dysexécutif, et
en symptômes non spécifiques comme le delirium.
La plupart de ces problèmes semblent provenir de
modifications neuropathologiques sous-corticales. La
dépression majeure est un diagnostic psychiatrique
courant, mais le syndrome dysexécutif, un trouble
difficile à définir dominé par une désinhibition et
une apathie souvent simultanées, pourrait être
encore plus répandu. Il n’existe pas de grandes
études contrôlées des traitements psychiatriques de
la MH. Des séries de cas, quelques rapports anecdo-
tiques et l’expérience clinique indiquent qu’un grand
nombre de ces syndromes répondent facilement au
traitement. La physiopathologie des maladies psy-
chiatriques de la population générale pourrait être
mieux comprise grâce à des études ultérieures sur la
neuropsychiatrie de la MH. 
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